| Severe Combined Immunodeficiency

Cuvitru vs Asceniv

Side-by-side clinical, coverage, and cost comparison for severe combined immunodeficiency.

Deep comparison between: Cuvitru vs Asceniv with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsAsceniv has a higher rate of injection site reactions vs Cuvitru based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Asceniv but not Cuvitru, including UnitedHealthcare

Category

Cuvitru

Asceniv

At A Glance

RouteSC injection

FrequencyDaily to every 2 weeks

ClassImmune globulin replacement (IgG)

RouteIV infusion

FrequencyEvery 3-4 weeks

ClassIgG replacement therapy

Indications

Common Variable Immunodeficiency
X-linked agammaglobulinemia
Congenital agammaglobulinemia
Wiskott-Aldrich Syndrome
Severe Combined Immunodeficiency

Congenital agammaglobulinemia
Common Variable Immunodeficiency
X-linked agammaglobulinemia
Wiskott-Aldrich Syndrome
Severe Combined Immunodeficiency

Dosing

Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency Individualized SC infusion administered daily to every 2 weeks; patients switching from IGIV begin 1 week after last IGIV dose with initial weekly dose (g) = previous IGIV dose (g) x 1.30 divided by weeks between IGIV doses; patients switching from IGSC use the same weekly dose; monitor serum IgG trough levels to guide adjustments.

Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300 to 800 mg/kg IV every 3 to 4 weeks; start infusion at 0.5 mg/kg/min for the first 15 minutes and increase gradually up to 8 mg/kg/min if tolerated.

Contraindications

Previous anaphylactic or severe systemic hypersensitivity reaction to subcutaneous administration of human immune globulin
IgA deficiency with antibodies against IgA and history of hypersensitivity to human immune globulin treatment

Previous anaphylactic or severe systemic reaction to human immune globulin
IgA deficiency with antibodies to IgA and history of hypersensitivity

Drug Interactions

163View drug interactions

Adverse Reactions

Most common (>=5%) Local adverse reactions, headache, nausea, fatigue, diarrhea, vomiting

Postmarketing Aseptic meningitis, anaphylactic reaction, tachycardia, tremor, paresthesia, dyspnea, laryngospasm, injection site reaction (induration, warmth), chest discomfort

Most common (>=5%) Headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, nausea

Postmarketing Apnea, ARDS, cyanosis, dyspnea, bronchospasm, cardiac arrest, vascular collapse, hypotension, coma, loss of consciousness, seizures, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, bullous dermatitis, pancytopenia, leukopenia, pyrexia, rigors, hepatic dysfunction, abdominal pain

Pharmacology

CUVITRU is a human IgG replacement product that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents, restoring abnormally low IgG levels to the normal range in patients with primary humoral immunodeficiency.

ASCENIV is an intravenous immunoglobulin replacement therapy that provides a broad spectrum of neutralizing IgG antibodies against bacterial and viral pathogens and their toxins; IgG antibodies act as opsonins to increase phagocytosis and elimination of pathogens from the circulation.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Cuvitru